Shionogi’s Xocova Cuts Risks of Long COVID by 45%: Exploratory Data

Shionogi’s oral COVID-19 treatment Xocova (ensitrelvir) slashed the risk of developing so-called “long COVID” symptoms by as much as 45%, according to the latest exploratory trial data for the drug, which received emergency approval in Japan last November. The exploratory...read more